Pre-Symptomatic Amyloid Disease Diagnosis

Amyloid diagnostics with single-molecule sensitivity

We are an R&D-driven BioMedTech company working on the translation of advanced spectroscopy methods for amyloid detection with single-molecule sensitivity to healthcare, most notably for early blood-based diagnosis of amyloid diseases such as Alzheimer’s disease.

Every 5 seconds an individual becomes affected by Alzheimer’s disease.

6 million new Alzheimer´s patients each year.

About 70 % of people living with Alzheimer’s disease remain undiagnosed.

About 30 % of people with Alzheimer’s disease diagnosis are wrongly diagnosed.

Our vision is to eradicate Alzheimer’s disease from the list of incurable diseases by bringing to healthcare our innovative quantitative analytical method for amyloid detection with single-molecule sensitivity and using it for pre-symptomatic blood-based amyloid disease diagnosis.

Our technology

We have invented a blood-based non-immune method that can detect pathological structured protein aggregates, so-called amyloid nano-plaques, with the ultimate single-molecule sensitivity and measure their concentration and size.

Our dedicated management team brings with enthusiasm, experience, and expertise new solutions to old-age-related health problems.

Technology inventors and AmyloiDia founders. From the left: Lars Terenius, Ann Tiiman, Vladana Vukojević, Jüri Jarvet, Rudolf Rigler, Astrid Gräslund and Sebastian Wärmländer. Missing: Johann Rigler.

Support

Contact us

Please contact us for further information and with any questions, we are very happy to help.